{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"7.1","value":"7.1"},{"groupId":"OG001","lowerLimit":"3.5","upperLimit":"4.5","value":"4"},{"groupId":"OG002","lowerLimit":"4.2","upperLimit":"6.7","value":"5.5"},{"groupId":"OG003","lowerLimit":"0.2","upperLimit":"3.2","value":"1.7"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"5.3","value":"4.6"},{"groupId":"OG005","lowerLimit":"7.9","upperLimit":"7.9","value":"7.9"},{"groupId":"OG006","lowerLimit":"5.0","upperLimit":"5.9","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Median (min,max) ratio of XPO1 mRNA expression after treatment to pre-treatment by study part, schema, and dose","dispersionType":"Full Range","groups":[{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course (Amendment 1)","id":"OG000","title":"Part A: Dose Level 1 (DL 1)"},{"description":"20 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course","id":"OG001","title":"Part A: Dose Level -1 (DL -1)"},{"description":"45 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG002","title":"Part A: Weekly Dose Level 1 (WDL 1)"},{"description":"35 mg/m2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG003","title":"Part A: Weekly Dose Level -1 (WDL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG004","title":"Part B: Weekly Dose Level -1 (WDL -1)"},{"description":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course","id":"OG005","title":"Part PK: Dose Level -1 (DL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG006","title":"Part PK: Weekly Dose Level -1 (WDL -1)"}],"paramType":"MEDIAN","populationDescription":"There were 0 (zero) patients from Part A: Dose Level 1 (Pre-amendment #1). Participation in the PD studies was optional. The subjects who had matched pre- and post-treatment blood samples were analyzed; not all the subjects had samples collected for PD analysis.","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Pharmacodynamics of Selinexor","type":"SECONDARY","unitOfMeasure":"Ratio of XPO1 mRNA expression"}